Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20688949 | 0.92 | JAK1 (0.45) | JAK1CYP1A1HPGDTYK2ACACB | |
| SCHEMBL20697290 | 0.84 | ALDH1A1 (0.41) | CYP1A1HPGDTYK2ALDH1A1JAK2 | |
| SCHEMBL21246014 | 0.82 | TP53 (0.46) | CYP1A1HPGDTYK2ALDH1A1JAK2 | |
| SCHEMBL20689569 | 0.81 | LMNA (0.41) | CYP1A1HPGDTYK2ALDH1A1KDM4E | |
| SCHEMBL20689606 | 0.81 | HPGD (0.36) | CYP1A1HPGDTYK2ALDH1A1KDM4E | |
| SCHEMBL20689010 | 0.81 | TYK2 (0.44) | CYP1A1HPGDTYK2JAK2NTRK1 | |
| SCHEMBL20688967 | 0.80 | KDM4E (0.41) | HPGDALDH1A1KDM4EPOLB | |
| SCHEMBL21246013 | 0.79 | LMNA (0.41) | CYP1A1HPGDALDH1A1KDM4EPOLB | |
| SCHEMBL20688901 | 0.79 | ALDH1A1 (0.45) | HPGDTYK2ALDH1A1KDM4EPOLB | |
| SCHEMBL20678811 | 0.79 | KDM4E (0.41) | HPGDALDH1A1KDM4EACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | JAK1 3/4885CYP1A1 4514/4885HPGD 4476/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | JAK1 3/4885CYP1A1 4514/4885HPGD 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.